Friday, October 30, 2026

Tech Sector

3 articles

Alphabet Raises 2026 Capex Guidance as Cloud Capacity Stays Supply-Constrained

Alphabet Raises 2026 Capex Guidance as Cloud Capacity Stays Supply-Constrained

Alphabet lifted its 2026 capital expenditure outlook after CFO Anat Ashkenazi said Google Cloud remains supply-constrained for a multiple consecutive quarters. The move puts Alphabet inside a roughly $650 billion 2026 spending envelope shared by four AI hyperscalers, raising the stakes for investors weighing capex against returns.

LM Salvado•
TSMC Lifts 2026 Capex Target After Record Q2, Boosting Equipment Makers

TSMC Lifts 2026 Capex Target After Record Q2, Boosting Equipment Makers

TSMC raised its 2026 capital spending target on July 16 after posting record second-quarter results, signaling sustained AI chip demand. Semiconductor equipment supplier Applied Materials is already up 121% year-to-date, and analysts are watching whether ASML and Lam Research follow the same trajectory.

LM Salvado•
AI Cloud Providers Pivot to Self-Built Data Centers as Infrastructure Bottlenecks Replace Chip Shortages

AI Cloud Providers Pivot to Self-Built Data Centers as Infrastructure Bottlenecks Replace Chip Shortages

CoreWeave and other specialized AI cloud providers are developing in-house data center construction capabilities as powered shell infrastructure has become the primary deployment constraint, not chip availability or power access. The shift marks a vertical integration push aimed at cutting deployment delays, with CoreWeave expecting to resolve the majority of current backlogs by Q1 2026.

ViaNews Editorial Team (Markets)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,503 source documents archived
Query this data → isubstrate.com